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Abstract²  . Starting from an HTS derived hit 1, application of biostructural data facilitated rapid optimization to lead 22, a novel 
AMPA receptor modulator. This is the first demonstration of how structure based drug design can be exploited in an optimization 
program for a glutamate receptor.©2010 Elsevier Science Ltd. All rights reserved. 
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The D-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptors are ionotropic 
glutamate receptors which are abundantly expressed in 
the central nervous system and are believed to facilitate 
the majority of fast excitatory amino acid 
neurotransmission. [1] The role of AMPA receptors 
appears to be critical to mediating synaptic plasticity 
and long-term potentiation (LTP), the use dependent 
enhancement in synaptic efficacy which is thought to 
encode various forms of learning and memory. AMPA 
receptor modulators have been shown to enhance LTP 
and are, therefore, under serious consideration as 
therapeutic agents for a range of neurological disorders 
LQFOXGLQJ VFKL]RSKUHQLD $O]KHLPHU¶V 'LVHDVH
3DUNLQVRQ¶VGLVHDVHDQG$'+'>2,3]  
 
Subunits of the AMPA receptor are encoded by 4 
distinct genes (GluA1 to 4), with each subunit 
comprising 4 domains: N-terminal, extracellular 
glutamate binding site (Ligand Binding domain, LBD), 
a transmembrane region and a C-terminal domain.[4]  In 
the last decade or so, significant advances have been 
made in studying the three-dimensional structure of the 
AMPA receptor with structures reported from a 
construct relating to the LBD (S1S2) [5] and latterly the  
 
 
 
full-length receptor.[6] 
 
Our research efforts were aimed at the identification of 
a novel series of AMPA receptor positive modulators 
which are of potential utility in the treatment of the 
kinds of neurological disorders delineated above.  
Following a high-throughput screening campaign using 
a functional assay with GluA1 overexpressed in HEK 
cells [7], we identified compound 1 (Figure 1) as a hit 
with confirmed activity from a well characterized solid 
sample. Compounds were inactive in the absence of 
glutamate, thus confirming their allosteric nature.  
 
While compound 1 represented a tractable chemotype 
amenable to optimization and was deemed to have 
satisfactory potency (pEC50 = 6.7), further in vitro 
profiling revealed a number of deficiencies that required 
attention.  Specifically, measured solubility was low (< 
1mg/L) and there were attendant issues with 
microsomal stability (Rat/human intrinsic clearance, 
CLi > 270 PL/min/mg protein).  
 
 From the outset of the program, we had access to 
biostructural data using the isolated S1S2 LBD GluA2 
construct [5] thus enabling an understanding of how our 
compounds interacted with the receptor.[8] Figure 1 
depicts hit compound 1 in complex with the S1S2 LBD 
GluA2 construct.[9] Although our biological assay used 
the GluA1 receptor (wild type GluA2 is not permeable 
to calcium), in our hands x-ray crystallographic study of 
selected compounds in both GluA1 and GluA2 
constructs showed the structures to be identical.[10]  
Given that structures could be more expediently 
obtained with GluA2, we selected this construct for 
routine examination. Modulators of the AMPA receptor 
bind remotely to the orthosteric site and essentially 
stabilize a protein-protein interaction between the 
receptor subunits of each ligand binding domain.[11] 
Analysis of our X-ray data revealed that the interactions 
made with the receptor were primarily hydrophobic in 
nature, with key contacts made at the distal ends of the 
molecule (CF3 moiety and tetrahydrobenzothiophene 
system).  From consideration of the biostructural data, 
three principal regions of the molecule were targeted 
(shown in red, green and blue) in order to address the 
solubility & metabolism issues (Figure 1).   
 
Modification of the tetrahydrobenzothiophene portion 
(shown in blue, Figure 1B) was expected to reduce 
lipophilicity and concomitantly improve potency and 
reduce propensity for hepatic metabolism.  However, it 
was also anticipated that modulatory activity at the 
AMPA receptor may be negatively impacted by such 
changes.  
 
 
 
 
 
 
 
Figure 1. A: Hit compound 1 in complex with S1S2 LBD of GluA2. 
Receptor surface is depicted, colored by atom type. Several residues have 
been omitted from this and subsequent figures for clarity. B: Highlighted 
in green, red and blue are the three regions targeted. 
 
Indeed, stripping back the fused cyclohexyl ring system 
to furnish e.g. compound 2 (Table 1) resulted in around 
a 30 fold reduction in potency, albeit with improvement 
observed in solubility (2 showed kinetic solubility of 10 
mg/L). Other truncated analogues (e.g. 3 and 4) showed 
a similar reduction in potency without any improvement 
in solubility. Retention of the fused ring system with 
incorporation of a heteroatom was next explored in 
order to attenuate lipophilicity.  Compound 5 displayed 
promising activity at the receptor but lacked any 
appreciable degree of solubility (< 1 mg/L) or metabolic 
stability (human and rat Cli > 270 PL/min/mg protein). 
Insertion of a basic amine (6) or introduction of a 
pendant alcohol (7) led to a more than ten-fold 
reduction in potency. 
 
Table 1. Modifications to the tetrahydrobenzothiophene region 
 
N
N
N
H
S
O
NH
2
F
3
C
O
R
2
R
1
 
 
Compds R1 R2 pEC50
a 
1 -(CH2)4- 6.7 
2 H H 5.2 
3 Me Me 6.1 
4 Et Me 6.2 
5 -CH2-CH2-O-CH2- 6.7 
6 -CH2-CH2-NH-CH2- 5.3 
7 CH2OH H 5.5 
aValues are means of two experiments performed in duplicate.  
 
In parallel, the contribution of the tetrahydroindazole 
system (shown in green, Figure 1B) to AMPA 
modulatory activity was examined (Table 2). Deletion 
of the fused cyclohexyl ring (8) resulted in 
approximately a 30-fold reduction in potency 
presumably due to loss of a non-specific hydrophobic 
interaction.  Activity could be partially restored by 
introduction of a 5-CF3 substituent (9), however again 
this was accompanied by low solubility and microsomal 
stability (Solubility < 1 mg/L, Cli (human) = 174 
PL/min/mg protein, Cli (rat) = 200 PL/min/mg protein). 
A fully aromatic system (10) exhibited promising 
GluA1 activity, however, was again compromised by 
inadequate solubility (< 1 mg/L) and less than optimal 
microsomal stability (Cli (human) = 153 L/min/mg 
protein, Cli (rat) = 91 PL/min/mg protein). As we 
expected from the biostructure of 1, having a correctly 
orientated trifluromethyl moiety is essential for activity. 
Replacement with a methyl (11) or altering the relative 
position (12) gave rise to inactive compounds. 
 
Table 2 Modifications to the tetrahydroindazole  region 
N
H
S
O
NH
2
O
R
 
Compds R pEC50
a 
 
8 
  
5.3 N
N
F
F
F
N
N
N
H
S
O
NH
2
F
3
C
O
  
 
9 
  
 
5.8 
 
 
10 
  
6.4 
 
11 
 
 
 
 
<4.5 
 
 
12 
  
 
<4.5 
aValues are means of two experiments performed in duplicate.  
 
The most effective means of meeting our optimization 
goals emerged from modification of the amide region of 
1. From consideration of the biostructural data, a 
hydrophilic pocket adjacent to the primary carboxamide 
motif (highlighted in red, Figure 1B) could be accessed 
by suitably functionalized entities. We, therefore, 
focused our efforts in making modifications to this 
region. Intially, simple carboxamide derivatives were 
prepared (e.g. 13, 14, Table 3) which confirmed that 
substitution at this position would be tolerated.  
Encouraged by these results, we next prepared a number 
of more functionalized derivatives with pendant 
solubilising groups. Evaluation of compound 15 in the 
GluA1 assay showed the compound had modest potency 
compared to our progenitor hit 1. However, it was 
sufficiently potent to obtain biostructural data (Figure 2) 
which revealed that contact with an Asp residue at the 
side of the hydrophilic pocket could be further 
optimized. We hypothesized that either modification of 
the linker length, or removal of one or both of the N,N-
dimethyl moieties could be beneficial to potency. In 
compound 15, the binding mode of the 
tetrahydroindazole region was essentially identical to 
that observed with the progenitor compound (1). 
 
Table 3. Modifications to the tetrahydrobenzothiophene region 
 
N
N
N
H
S
O
NH
F
3
C
O
R
 
Compds R pEC50
a 
13 Et 6.5 
14 cPropyl 6.2 
15 -CH2CH2NMe2 5.2 
16 -(CH2)3-NH2 6.4 
17 -CH2CH2NHMe 5.7 
18 -(CH2)4-NH2 5.9 
19 -CH2CH2NH2 5.8 
20 -CH2CH2OH 7.3 
21 -CH2CH2NHSO2Me 7.0 
aValues are means of two experiments performed in duplicate 
 
These considerations led to the design of compound 16 
which had comparable potency to the original hit. Other 
amine derivatives (e.g. 17-19), although more potent 
than the progenitor 15, were not as active at the receptor 
compared to compound 16.  The hydrophilic region 
proved to be relatively tolerant of other functional 
groups with alcohols typified by 20 and sulfonamide 
derivatives such as 21 displaying impressive potencies 
but in common with many other members of the series 
lacked solubility or microsomal stability. 
 
 
 
Figure 2. Biostructure of compound 15 in complex with the S1S2 LBD 
of GluA2. 
 
In the series as a whole, compound 16 displayed the 
best balance of solubility (38 mg/L) and microsomal 
stability (human Cli = 17 PL/min/mg protein, rat Cli = 
77 PL/min/mg protein). Permeability as measured by 
CaCo-2 was deemed to be low, however there was no 
indication of efflux (A-B = 34 nm/s, B-A = 55 nm/s). In 
vivo pharmacokinetics in Wistar rats (2 mg/kg i.v., 10 
mg/kg p.o.) indicated moderate clearance & half life in 
the i.v. leg (Clp = 21 mL/min/kg, T1/2 = 3.2 h, Vss = 3.8 
L/kg), however, as anticipated from the CaCo-2 data, 
observed oral bioavailability was low (7.7%). Brain to 
plasma ratio was low (0.05) which was reasoned to be a 
function of both the number of hydrogen bond donors 
and rotatable bonds present in the molecule. 
 
X-ray crystallographic data on the complex of 16 with 
the S1S2 LBD revealed the binding mode was as 
anticipated based on our observations from compound 
15 (Figure 3). The propylamine side chain was shown to 
project into the hydrophilic pocket as before, but now 
forming a salt-bridge with the sidechain of Asp 760. 
The biostructural data also suggested that 
conformationally constrained analogues of 16 could be 
accommodated in the hydrophilic region and this led to 
the design and synthesis of analogues 22-25 (Table 4) in 
an effort to improve brain penetration and oral 
bioavailability.  
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Figure 3. X-ray structure of 16 in complex with the S1S2 LBD of GluA2 
 
Comparing 22 and 23 shows a preference for the (R) 
stereochemistry on the pyrrolidine ring system. This 
was consistent with our expectations based on the 
conformation of the propylamine moiety required to 
facilitate the salt-bridge with Asp 760.  The azetidine 
analogues 24 and 25 show similar potencies at GluA1 
compared to 22. 
 
Table 4. Constrained analogues of compound 16. 
 
N
N
N
H
S
O
NH
F
3
C
O
R
 
Compds R pEC50
a 
 
22 
  
6.6 
 
23 
 
 
 
 
5.8 
 
24 
 
 
 
6.5 
 
25 
 
 
 
 
6.2 
aValues are means of two experiments performed in duplicate 
 
Further profiling of 22 indicated that the compound had 
both reasonable solubility (20 mg/L) and microsomal 
stability (human Cli = 41 PL/min/mg protein, rat Cli = 
50 PL/min/mg protein).  Assessment of permeability in 
the CaCo-2 assay suggested that absorption might still 
be an issue (A-B = 19 nm/s, B-A = 22 nm/s).  In vivo 
pharmacokinetics in rat (2 mg/kg i.v., 10 mg/kg p.o.) 
indicated that 22 had low clearance and a reasonable 
half-life (Clp = 2.3 mL/min/kg, T1/2 = 3.8 h, Vss = 0.5 
L/kg) and significantly improved brain exposure (brain : 
plasma ratio = 1.03).  However, measured oral 
bioavailability was still low (3.8%) indicating that 
conformational constraint alone was not sufficient to 
enhance this important parameter.  
 
Synthetic approaches to the compounds discussed above 
are outlined in Schemes 1 to 3. Compounds 1-7 were 
prepared through a Gewald cyclisation [12] to prepare 
the requisite tertrahydrobenzothiophene systems (27) 
followed by HATU mediated coupling to furnish 
compounds 1 to 7. 
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Scheme 1. Reagents and conditions: a) sulfur, cyanoacetamide, 
diethylamine, EtOH, reflux 23-51%; b) 3-trifluoromethyl-4,5,6,7-
tetrahydroindazol-1-yl)-acetic acid, PS-CDI, PW, 120°C, 10-53%; c) 
TFA/CH2Cl2, rt, 23% (for 6). 
 
Compounds 8 to 12 were synthesized in a two step 
fashion from the available amino thiophene derivative 
28 (Scheme 2).  Acetylation with bromacetyl bromide 
followed by alkylation of the appropriate azole 
derivative furnished the requisite target molecules in an 
expedient fashion. 
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Scheme 2. Reagents and conditions: a) bromoacetyl bromide, Et3N, 
CH2Cl2, rt, 94%; b) azole derivative, NaH, DMF, 0° to rt, 14-49%. 
 
Amide derivatives 13 to 25 were accessed as depicted in 
Scheme 3. Starting from cyclohexanone, Gewald 
cyclisation furnished the aminothiophene ester 30. 
Amide coupling provided intermediate 31 which was 
deprotected by acidolysis. Subsequent HATU mediated 
amide formation provided amides 13 to 15 and 20/21. In 
the case of 16 to 19 and 22 to 25, a Boc protected 
diamine derivative is employed in the coupling step 
with the desired amine unmasked in a final TFA 
deprotection step. 
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Scheme 3. Reagents and conditions: a) sulfur, tert-butylcyanoacetate, 
diethylamine, EtOH, reflux, 95%; b) (3-trifluoromethyl-4,5,6,7-
tetrahydroindazol-1-yl)-acetic acid, HATU, DIEA, CH2Cl2/DMF, rt, 75%; 
c) TFA/CH2Cl2, rt, quant.; d) amine/Boc-diamine, HATU, DIEA, DMF, rt 
10-70%; e) TFA/CH2Cl2 (for 16 to 19 and 22 to 25), 15-40%. 
 
In summary, we have demonstrated how hit compound 
1 was rapidly optimized to improve physicochemical 
NH
N
H
N
H
NH
 parameters and metabolic stability resulting in 
compounds such as 16 and 22. A central component of 
our expedient optimization trajectory has been the 
application of structure-based drug design and is the 
first example of its use in a glutamate receptor system. 
Compounds such as 22 are useful tools in further 
elucidating the role of AMPA receptor modulators in 
debiOLWDWLQJQHXURORJLFDOGLVRUGHUV VXFKDV$O]KHLPHU¶V
'LVHDVH DQG 3DUNLQVRQ¶V  ,Q WKH IROORZLQJ SDSHU ZH
describe how 22 can be further optimized to an orally 
bioavailable AMPA receptor modulator with promising 
in vivo activity. 
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